Why weight loss feels slow on Wegovy — and what's actually happening

You've been on it for six weeks and the number hasn't moved much

Six weeks in, many people are still on 0.25 mg or 0.5 mg, the doses that exist to let your digestive system adjust, not to produce the losses shown in trial data. The STEP 1 trial, published in the New England Journal of Medicine, ran for 68 weeks; the meaningful weight-loss curve accelerated once participants reached the higher doses, typically after several months of titration. At six weeks, you may simply not be there yet.

There's also a common misconception worth putting to rest gently: appetite suppression isn't always dramatic at first. Some people feel it immediately; others notice it gradually as the dose climbs. Slower appetite changes early on don't predict poor outcomes later. The full picture of how Wegovy works for weight management explains why the titration period matters as much as the maintenance dose.

One practical check: are you eating less, sleeping similarly, and moving at roughly the same level as before? If your intake has actually fallen but the scales are flat, fluid shifts and digestive changes in the first weeks of treatment can mask real fat loss. The number will catch up.

What slows Wegovy's effect mid-treatment

Once you reach the 1.7 mg or 2.4 mg dose, weight loss that was moving can sometimes slow down, or stop for a stretch. Several things account for this. The body adjusts its resting metabolism as weight falls, meaning the same calorie deficit produces less loss over time. Protein intake, activity level, sleep quality and stress all interact with how the medicine performs. None of that means Wegovy has stopped working; it means biology is doing what biology does.

Plateaus lasting two to four weeks are normal and don't require intervention on their own. A plateau lasting two months at maintenance dose is worth discussing with your prescriber. Under the terms of the NICE appraisal of semaglutide (TA875), continuing treatment is reviewed if less than 5% weight loss has occurred after six months on the maintenance dose, that's a clinical threshold, not a reason to panic at week ten.

For context on what the data shows at different stages of treatment, the semaglutide and weight loss evidence page works through the trial figures and how individual variation plays out. It's a useful reference before drawing conclusions from your own early results.

Practical steps that tend to help

The medicine lowers appetite; what you do with that is still part of the equation. People who see the steadiest results tend to prioritise protein at each meal, it preserves muscle as fat is lost, and muscle burns more energy at rest. Hydration matters too, because thirst is easily mistaken for hunger, and some gastrointestinal side effects ease when fluid intake is consistent.

Physical activity doesn't have to be intense. Consistent walking, two sessions of resistance work a week, and keeping sleep regular all support what semaglutide is already doing. The NHS Better Health resources at nhs.uk/better-health/lose-weight set out straightforward lifestyle guidance that sits alongside medical treatment.

Cost can be a factor in whether people stay on treatment long enough to see the results the evidence shows. The Wegovy cost page covers what private treatment typically involves in the UK and what an honest price should include. Stopping and restarting is rarely better than a consistent, properly supervised course, if affordability is the issue, it's worth raising with your prescriber rather than simply pausing.

When to raise slow progress with a prescriber, and what they'll consider

Slow weight loss on Wegovy is not by itself a clinical emergency, but it is a clinical question. A prescriber can review whether you're at the right dose for your situation, whether there are any interactions or conditions affecting response, and whether the plan needs adjusting. That conversation belongs with a clinician, not a forum.

Some people ask whether switching to a different medicine would help. That's a reasonable question, tirzepatide, available in the UK as Mounjaro, acts on two receptors rather than one, and produced greater average weight reduction than semaglutide 2.4 mg in the SURMOUNT-5 head-to-head trial. Whether a switch makes sense depends on clinical factors, not just comparison charts. Our semaglutide overview and the Wegovy page both set out what's known, and a detailed comparison lives on the weight-loss medicines page.

At nume, a named GPhC-registered Independent Prescriber reads your consultation personally (a real clinician, not software) on the same day. If you're already on treatment and your progress feels stuck, or if you're considering starting and want the picture set out honestly, checking your eligibility with our prescribers is a sensible next step.